BioNTech SE has provided further details on the company’s R&D effort, “Project Lightspeed,” to develop a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.   BioNTech intends to initiate clinical testing for BNT162 in late April 2020, subject to regulatory approval, as part of a global...